NEWS!

  • 16/05/2023

Recent technical developments such as the online activity monitoring during implantation and the definition of Key Performance Indicators for MEDICIS were reported at EMIS2022 and IPAC2023 conferences. Related EMIS and IPAC publications.

  • 10/03/2023

Three new project proposals were submitted at the 10th MEDICIS Collaboration board, with a notable request to translate one of the MEDICIS High Molar Activity radionuclides in a clinical settings.

  • 15/11/2022

The Frontiers Research Topics : MEDICIS-Promed, Advances in Radioactive Ion Beams for Nuclear Medicine is now published. It can be downloaded from there.

  • 26/09/2022

The half-life of Tb-155 produced at MEDICIS has been revised and is now published by S. Collins et al. in Applied Radiation and Isotope. High molar activity Sm-153 was 1st used in Targeted Radionuclide Therapy and theranostics (MED-025) by M. Ooms et al, as presented at TERACHEM.

 

JOB OPPORTUNITIES

  • Please check out regularly

A KNOWLEDGE TRANSFER SUCCESS STORY

Read more ...

GRANTS & DONATIONS - CERN & Society Foundation

The CERN KT-Fund

La Fondation pour l'innovation sur le cancer et la biologie

The ADAM company

The FWO

  PRISMAP and EURAMED in H2020 European commission